XML 74 R51.htm IDEA: XBRL DOCUMENT
v3.22.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jul. 03, 2022 | Jul. 04, 2021 | Jul. 03, 2022 | Jul. 04, 2021
Sales by segment of business |  |  |  |
Sales to customers | $ 24,020 | $ 23,312 | $ 47,446 | $ 45,633
Percent Change (as a percent) | 3.00% |  | 4.00% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12,197 | 11,919 | $ 23,611 | 23,030
Percent Change (as a percent) | 2.30% |  | 2.50% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 11,823 | 11,393 | $ 23,835 | 22,603
Percent Change (as a percent) | 3.80% |  | 5.50% |
CONSUMER HEALTH (1) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,805 | 3,854 | $ 7,391 | 7,495
Percent Change (as a percent) | (1.30%) |  | (1.40%) |
CONSUMER HEALTH (1) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,687 | 1,751 | $ 3,244 | 3,362
Percent Change (as a percent) | (3.60%) |  | (3.50%) |
CONSUMER HEALTH (1) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,118 | 2,103 | $ 4,147 | 4,133
Percent Change (as a percent) | 0.60% |  | 0.30% |
CONSUMER HEALTH (1) | OTC [Member] |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,482 | 1,426 | $ 2,943 | 2,699
Percent Change (as a percent) | 3.80% |  | 9.00% |
CONSUMER HEALTH (1) | OTC [Member] | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 663 | 675 | $ 1,333 | 1,274
Percent Change (as a percent) | (1.80%) |  | 4.60% |
CONSUMER HEALTH (1) | OTC [Member] | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 818 | 752 | $ 1,609 | 1,425
Percent Change (as a percent) | 8.80% |  | 12.90% |
CONSUMER HEALTH (1) | Skin Health/Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,126 | 1,170 | $ 2,138 | 2,333
Percent Change (as a percent) | (3.70%) |  | (8.30%) |
CONSUMER HEALTH (1) | Skin Health/Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 629 | 659 | $ 1,173 | 1,293
Percent Change (as a percent) | (4.50%) |  | (9.20%) |
CONSUMER HEALTH (1) | Skin Health/Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 497 | 511 | $ 965 | 1,040
Percent Change (as a percent) | (2.80%) |  | (7.20%) |
CONSUMER HEALTH (1) | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 394 | 426 | $ 760 | 843
Percent Change (as a percent) | (7.30%) |  | (9.70%) |
CONSUMER HEALTH (1) | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 165 | $ 313 | 328
Percent Change (as a percent) | 3.40% |  | (4.60%) |
CONSUMER HEALTH (1) | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 224 | 260 | $ 447 | 514
Percent Change (as a percent) | (14.10%) |  | (13.00%) |
CONSUMER HEALTH (1) | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 375 | 387 | $ 730 | 776
Percent Change (as a percent) | (3.10%) |  | (5.90%) |
CONSUMER HEALTH (1) | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 88 | 97 | $ 173 | 193
Percent Change (as a percent) | (9.10%) |  | (10.30%) |
CONSUMER HEALTH (1) | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 287 | 290 | $ 557 | 583
Percent Change (as a percent) | (1.00%) |  | (4.40%) |
CONSUMER HEALTH (1) | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 230 | 230 | $ 458 | 452
Percent Change (as a percent) | 0.20% |  | 1.40% |
CONSUMER HEALTH (1) | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 7 | 6
Percent Change (as a percent) | 8.90% |  | 8.10% |
CONSUMER HEALTH (1) | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 228 | 227 | $ 452 | 446
Percent Change (as a percent) | 0.10% |  | 1.30% |
CONSUMER HEALTH (1) | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 197 | 216 | $ 361 | 393
Percent Change (as a percent) | (8.40%) |  | (8.00%) |
CONSUMER HEALTH (1) | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 153 | $ 245 | 268
Percent Change (as a percent) | (12.70%) |  | (8.60%) |
CONSUMER HEALTH (1) | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 65 | 64 | $ 117 | 125
Percent Change (as a percent) | 1.70% |  | (6.60%) |
PHARMACEUTICAL(1) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13,317 | 12,480 | $ 26,186 | 24,581
Percent Change (as a percent) | 6.70% |  | 6.50% |
PHARMACEUTICAL(1) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,159 | 6,869 | $ 13,791 | 13,315
Percent Change (as a percent) | 4.20% |  | 3.60% |
PHARMACEUTICAL(1) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,158 | 5,611 | $ 12,395 | 11,266
Percent Change (as a percent) | 9.80% |  | 10.00% |
PHARMACEUTICAL(1) | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,411 | 4,231 | $ 8,530 | 8,145
Percent Change (as a percent) | 4.30% |  | 4.70% |
PHARMACEUTICAL(1) | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,853 | 2,748 | $ 5,354 | 5,161
Percent Change (as a percent) | 3.80% |  | 3.70% |
PHARMACEUTICAL(1) | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,559 | 1,483 | $ 3,176 | 2,984
Percent Change (as a percent) | 5.10% |  | 6.40% |
PHARMACEUTICAL(1) | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 647 | 888 | $ 1,310 | 1,665
Percent Change (as a percent) | (27.20%) |  | (21.40%) |
PHARMACEUTICAL(1) | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 391 | 540 | $ 749 | 1,029
Percent Change (as a percent) | (27.40%) |  | (27.10%) |
PHARMACEUTICAL(1) | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 44 | 93 | $ 124 | 150
Percent Change (as a percent) | (53.00%) |  | (17.50%) |
PHARMACEUTICAL(1) | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 212 | 255 | $ 437 | 487
Percent Change (as a percent) | (17.20%) |  | (10.30%) |
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 566 | 584 | $ 1,137 | 1,146
Percent Change (as a percent) | (3.00%) |  | (0.80%) |
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 301 | 290 | $ 588 | 545
Percent Change (as a percent) | 3.80% |  | 7.90% |
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 266 | 294 | $ 549 | 601
Percent Change (as a percent) | (9.70%) |  | (8.60%) |
PHARMACEUTICAL(1) | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,599 | 2,274 | $ 4,887 | 4,422
Percent Change (as a percent) | 14.30% |  | 10.50% |
PHARMACEUTICAL(1) | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,731 | 1,496 | $ 3,110 | 2,827
Percent Change (as a percent) | 15.70% |  | 10.00% |
PHARMACEUTICAL(1) | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 868 | 778 | $ 1,777 | 1,595
Percent Change (as a percent) | 11.60% |  | 11.40% |
PHARMACEUTICAL(1) | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 597 | 479 | $ 1,187 | 897
Percent Change (as a percent) | 24.40% |  | 32.30% |
PHARMACEUTICAL(1) | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 382 | 325 | $ 773 | 599
Percent Change (as a percent) | 17.70% |  | 29.10% |
PHARMACEUTICAL(1) | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 214 | 155 | $ 413 | 298
Percent Change (as a percent) | 38.30% |  | 38.60% |
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 7 | $ 9 | 15
Percent Change (as a percent) | (59.20%) |  | (39.00%) |
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 5 | $ 9 | 12
Percent Change (as a percent) | (50.10%) |  | (24.80%) |
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 1 | $ 0 | 3
PHARMACEUTICAL(1) | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,316 | 1,018 | $ 2,613 | 2,016
Percent Change (as a percent) | 29.30% |  | 29.60% |
PHARMACEUTICAL(1) | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 415 | 444 | $ 876 | 956
Percent Change (as a percent) | (6.40%) |  | (8.30%) |
PHARMACEUTICAL(1) | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 901 | 575 | $ 1,737 | 1,060
Percent Change (as a percent) | 56.80% |  | 63.90% |
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 544 | 164 | $ 1,001 | 264
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 45 | 51 | $ 120 | 151
Percent Change (as a percent) | (11.50%) |  | (20.40%) |
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 499 | 113 | $ 881 | 113
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 225 | 262 | $ 473 | 505
Percent Change (as a percent) | (14.30%) |  | (6.50%) |
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9 | 9 | $ 18 | 19
Percent Change (as a percent) | (1.70%) |  | (7.40%) |
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 215 | 253 | $ 454 | 486
Percent Change (as a percent) | (14.70%) |  | (6.50%) |
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 464 | 505 | $ 965 | 1,051
Percent Change (as a percent) | (7.90%) |  | (8.10%) |
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 355 | 368 | $ 724 | 748
Percent Change (as a percent) | (3.40%) |  | (3.20%) |
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 110 | 137 | $ 242 | 303
Percent Change (as a percent) | (20.20%) |  | (20.30%) |
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 83 | 88 | $ 174 | 196
Percent Change (as a percent) | (5.40%) |  | (10.90%) |
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6 | 16 | $ 14 | 37
Percent Change (as a percent) | (62.50%) |  | (62.50%) |
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 77 | 71 | $ 160 | 158
Percent Change (as a percent) | 7.40% |  | 1.30% |
PHARMACEUTICAL(1) | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,734 | 1,804 | $ 3,475 | 3,519
Percent Change (as a percent) | (3.90%) |  | (1.20%) |
PHARMACEUTICAL(1) | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 896 | 842 | $ 1,739 | 1,613
Percent Change (as a percent) | 6.50% |  | 7.90% |
PHARMACEUTICAL(1) | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 837 | 963 | $ 1,735 | 1,906
Percent Change (as a percent) | (13.00%) |  | (8.90%) |
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 161 | 161 | $ 318 | 332
Percent Change (as a percent) | 0.30% |  | (4.10%) |
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 38 | 35 | $ 73 | 82
Percent Change (as a percent) | 9.40% |  | (11.30%) |
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 123 | 127 | $ 245 | 250
Percent Change (as a percent) | (2.20%) |  | (1.70%) |
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,054 | 1,024 | $ 2,102 | 1,989
Percent Change (as a percent) | 2.90% |  | 5.70% |
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 691 | 645 | $ 1,352 | 1,234
Percent Change (as a percent) | 7.30% |  | 9.60% |
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 362 | 380 | $ 749 | 756
Percent Change (as a percent) | (4.60%) |  | (0.80%) |
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 125 | 155 | $ 254 | 312
Percent Change (as a percent) | (19.30%) |  | (18.40%) |
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 65 | 72 | $ 128 | 139
Percent Change (as a percent) | (8.90%) |  | (7.70%) |
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 60 | 84 | $ 126 | 173
Percent Change (as a percent) | (28.00%) |  | (27.10%) |
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 393 | 464 | $ 800 | 886
Percent Change (as a percent) | (15.20%) |  | (9.60%) |
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 102 | 91 | $ 186 | 158
Percent Change (as a percent) | 11.80% |  | 17.60% |
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 292 | 373 | $ 615 | 728
Percent Change (as a percent) | (21.80%) |  | (15.50%) |
PHARMACEUTICAL(1) | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,042 | 3,535 | $ 7,992 | 7,105
Percent Change (as a percent) | 14.30% |  | 12.50% |
PHARMACEUTICAL(1) | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,679 | 1,462 | $ 3,261 | 2,839
Percent Change (as a percent) | 14.90% |  | 14.90% |
PHARMACEUTICAL(1) | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,362 | 2,073 | $ 4,731 | 4,266
Percent Change (as a percent) | 14.00% |  | 10.90% |
PHARMACEUTICAL(1) | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,986 | 1,433 | $ 3,842 | 2,798
Percent Change (as a percent) | 38.60% |  | 37.30% |
PHARMACEUTICAL(1) | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,021 | 770 | $ 1,974 | 1,461
Percent Change (as a percent) | 32.60% |  | 35.10% |
PHARMACEUTICAL(1) | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 965 | 663 | $ 1,868 | 1,337
Percent Change (as a percent) | 45.50% |  | 39.70% |
PHARMACEUTICAL(1) | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 450 | 302 | $ 850 | 563
Percent Change (as a percent) | 49.50% |  | 51.10% |
PHARMACEUTICAL(1) | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 233 | 193 | $ 439 | 364
Percent Change (as a percent) | 20.60% |  | 20.40% |
PHARMACEUTICAL(1) | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 218 | 109 | $ 412 | 199
PHARMACEUTICAL(1) | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 970 | 1,116 | $ 2,008 | 2,241
Percent Change (as a percent) | (13.10%) |  | (10.40%) |
PHARMACEUTICAL(1) | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 349 | 454 | $ 719 | 898
Percent Change (as a percent) | (23.10%) |  | (19.90%) |
PHARMACEUTICAL(1) | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 620 | 662 | $ 1,288 | 1,342
Percent Change (as a percent) | (6.30%) |  | (4.00%) |
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 505 | 563 | $ 1,044 | 1,201
Percent Change (as a percent) | (10.30%) |  | (13.10%) |
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 19 | 21 | $ 38 | 71
Percent Change (as a percent) | (12.20%) |  | (47.00%) |
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 486 | 542 | $ 1,006 | 1,130
Percent Change (as a percent) | (10.20%) |  | (11.00%) |
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 130 | 120 | $ 248 | 302
Percent Change (as a percent) | 7.50% |  | (18.00%) |
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 57 | 23 | $ 91 | 44
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 72 | 97 | $ 156 | 258
Percent Change (as a percent) | (25.70%) |  | (39.40%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 843 | 870 | $ 1,695 | 1,731
Percent Change (as a percent) | (3.10%) |  | (2.10%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 560 | 595 | $ 1,132 | 1,168
Percent Change (as a percent) | (5.80%) |  | (3.10%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 284 | 275 | $ 563 | 563
Percent Change (as a percent) | 2.80% |  | (0.10%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 438 | 463 | $ 881 | 913
Percent Change (as a percent) | (5.30%) |  | (3.50%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 265 | 290 | $ 538 | 562
Percent Change (as a percent) | (8.70%) |  | (4.30%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 173 | 172 | $ 343 | 351
Percent Change (as a percent) | 0.50% |  | (2.20%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 328 | 313 | $ 653 | 618
Percent Change (as a percent) | 4.90% |  | 5.70% |
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 272 | 268 | $ 541 | 527
Percent Change (as a percent) | 1.40% |  | 2.60% |
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 56 | 45 | $ 112 | 91
Percent Change (as a percent) | 26.20% |  | 23.50% |
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 78 | 95 | $ 161 | 200
Percent Change (as a percent) | (18.70%) |  | (19.80%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 23 | 36 | $ 53 | 78
Percent Change (as a percent) | (36.20%) |  | (32.30%) |
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 59 | $ 108 | 122
Percent Change (as a percent) | (8.10%) |  | (11.70%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 972 | 1,021 | $ 1,882 | 2,065
Percent Change (as a percent) | (4.80%) |  | (8.90%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 757 | 780 | $ 1,429 | 1,579
Percent Change (as a percent) | (3.00%) |  | (9.50%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 215 | 241 | $ 453 | 486
Percent Change (as a percent) | (10.90%) |  | (6.90%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 609 | 569 | $ 1,117 | 1,158
Percent Change (as a percent) | 7.10% |  | (3.50%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 609 | 569 | $ 1,117 | 1,158
Percent Change (as a percent) | 7.10% |  | (3.50%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 120 | 160 | $ 248 | 310
Percent Change (as a percent) | (24.90%) |  | (19.90%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 96 | $ 115 | 183
Percent Change (as a percent) | (42.90%) |  | (37.10%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 65 | 64 | $ 133 | 127
Percent Change (as a percent) | 2.40% |  | 4.90% |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 243 | 293 | $ 517 | 598
Percent Change (as a percent) | (17.20%) |  | (13.50%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 93 | 116 | $ 197 | 238
Percent Change (as a percent) | (19.50%) |  | (17.20%) |
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 150 | 178 | $ 320 | 360
Percent Change (as a percent) | (15.60%) |  | (11.10%) |
MEDTECH(3) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,898 | 6,978 | $ 13,869 | 13,557
Percent Change (as a percent) | (1.10%) |  | 2.30% |
MEDTECH(3) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,351 | 3,299 | $ 6,576 | 6,353
Percent Change (as a percent) | 1.60% |  | 3.50% |
MEDTECH(3) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,547 | 3,679 | $ 7,293 | 7,204
Percent Change (as a percent) | (3.60%) |  | 1.20% |
MEDTECH(3) | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,049 | 1,046 | $ 2,141 | 1,995
Percent Change (as a percent) | 0.30% |  | 7.40% |
MEDTECH(3) | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 525 | 475 | $ 1,019 | 909
Percent Change (as a percent) | 10.50% |  | 12.10% |
MEDTECH(3) | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 525 | 572 | $ 1,123 | 1,086
Percent Change (as a percent) | (8.10%) |  | 3.40% |
MEDTECH(3) | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,157 | 2,227 | $ 4,345 | 4,340
Percent Change (as a percent) | (3.10%) |  | 0.10% |
MEDTECH(3) | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,338 | 1,323 | $ 2,627 | 2,572
Percent Change (as a percent) | 1.10% |  | 2.10% |
MEDTECH(3) | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 820 | 904 | $ 1,719 | 1,768
Percent Change (as a percent) | (9.30%) |  | (2.80%) |
MEDTECH(3) | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 388 | 391 | $ 777 | 747
Percent Change (as a percent) | (0.70%) |  | 4.10% |
MEDTECH(3) | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 240 | 233 | $ 465 | 442
Percent Change (as a percent) | 3.40% |  | 5.20% |
MEDTECH(3) | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 148 | 159 | $ 312 | 305
Percent Change (as a percent) | (6.60%) |  | 2.40% |
MEDTECH(3) | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 349 | 350 | $ 688 | 667
Percent Change (as a percent) | (0.10%) |  | 3.10% |
MEDTECH(3) | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 216 | 210 | $ 417 | 395
Percent Change (as a percent) | 2.90% |  | 5.60% |
MEDTECH(3) | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 140 | $ 271 | 272
Percent Change (as a percent) | (4.60%) |  | (0.40%) |
MEDTECH(3) | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 696 | 710 | $ 1,444 | 1,443
Percent Change (as a percent) | (1.90%) |  | 0.10% |
MEDTECH(3) | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 464 | 447 | $ 939 | 897
Percent Change (as a percent) | 3.90% |  | 4.70% |
MEDTECH(3) | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 232 | 263 | $ 505 | 545
Percent Change (as a percent) | (11.80%) |  | (7.40%) |
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 724 | 777 | $ 1,436 | 1,484
Percent Change (as a percent) | (6.80%) |  | (3.20%) |
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 418 | 434 | $ 805 | 838
Percent Change (as a percent) | (3.70%) |  | (3.90%) |
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 306 | 343 | $ 630 | 646
Percent Change (as a percent) | (10.60%) |  | (2.40%) |
MEDTECH(3) | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,450 | 2,522 | $ 4,884 | 4,894
Percent Change (as a percent) | (2.80%) |  | (0.20%) |
MEDTECH(3) | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 992 | 1,035 | $ 1,913 | 1,933
Percent Change (as a percent) | (4.10%) |  | (1.00%) |
MEDTECH(3) | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,458 | 1,487 | $ 2,971 | 2,961
Percent Change (as a percent) | (2.00%) |  | 0.30% |
MEDTECH(3) | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,156 | 1,168 | $ 2,302 | 2,286
Percent Change (as a percent) | (1.00%) |  | 0.70% |
MEDTECH(3) | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 454 | 459 | $ 871 | 864
Percent Change (as a percent) | (1.10%) |  | 0.80% |
MEDTECH(3) | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 702 | 708 | $ 1,431 | 1,421
Percent Change (as a percent) | (0.90%) |  | 0.70% |
MEDTECH(3) | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,294 | 1,354 | $ 2,582 | 2,608
Percent Change (as a percent) | (4.50%) |  | (1.00%) |
MEDTECH(3) | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 538 | 576 | $ 1,042 | 1,069
Percent Change (as a percent) | (6.40%) |  | (2.50%) |
MEDTECH(3) | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 756 | 779 | $ 1,540 | 1,540
Percent Change (as a percent) | (3.00%) |  | 0.00% |
MEDTECH(3) | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,241 | 1,183 | $ 2,498 | 2,328
Percent Change (as a percent) | 4.90% |  | 7.30% |
MEDTECH(3) | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 496 | 467 | $ 1,017 | 939
Percent Change (as a percent) | 6.20% |  | 8.30% |
MEDTECH(3) | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 745 | 716 | $ 1,481 | 1,389
Percent Change (as a percent) | 4.00% |  | 6.60% |
MEDTECH(3) | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 894 | 868 | $ 1,804 | 1,725
Percent Change (as a percent) | 2.90% |  | 4.50% |
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 374 | 352 | $ 774 | 723
Percent Change (as a percent) | 6.60% |  | 7.20% |
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 519 | 517 | $ 1,030 | 1,003
Percent Change (as a percent) | 0.40% |  | 2.70% |
MEDTECH(3) | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 347 | 314 | $ 694 | 602
Percent Change (as a percent) | 10.50% |  | 15.20% |
MEDTECH(3) | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 122 | 115 | $ 243 | 216
Percent Change (as a percent) | 5.10% |  | 12.10% |
MEDTECH(3) | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 225 | 199 | $ 451 | 386
Percent Change (as a percent) | 13.60% |  | 17.00% |
CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers |  | $ 100 |  | $ 200

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |